We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
Read MoreHide Full Article
Axsome Therapeutics, Inc. (AXSM - Free Report) announced mixed top-line data from the phase III STRIDE-1 study evaluating its pipeline candidate AXS-05 to address patients with treatment resistant depression (TRD).
The primary endpoint following the week six of treatment did not reach any statistical significance in the above-mentioned study.
Nevertheless, the candidate met key secondary endpoints by demonstrating rapid and statistically significant improvements in depressive symptoms, per the Montgomery-Åsberg Depression Rating Scale (MADRS) measure at week one and for the overall six-week treatment period compared to the active comparator bupropion in the given patient population.
This randomized, double-blind, active-controlled study is assessing the safety and efficacy of AXS-05 for the aforementioned patient population. Based on results from the STRIDE-1 study, Axsome plans to initiate a second phase III study on AXS-05 in the third quarter of 2020 for addressing patients with TRD.
Shares of Axsome have skyrocketed 326.2% in the past year against the industry’s decline of 11.8%.
AXS-05 is a novel, oral, investigational non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity under development for treating central nervous system (CNS) disorder. Apart from the STRIDE-1 study, Axsome is conducting a phase III GEMINI study on AXS-05 for treating major depressive disorder (MDD) as well as a phase II/III ADVANCE-1 study on agitation associated with Alzheimer's disease (AD).
Per the company, positive outcomes from GEMINI study on MDD along with the previously-completed ASCEND study will be sufficient to support the filing of a new drug application (NDA) for AXS-05 to treat MDD. The NDA is expected to be filed in the fourth quarter of 2020.
In March 2020, Axsome announced that it is accelerating the completion time of the phase II/III ADVANCE-1 study on AXS-05. As a result, top-line findings from the study are now expected in early second-quarter 2020, which were previously awaited in the third. The study is currently enrolling patients aged 65 years and above.
Acorda’s loss per share estimates have narrowed 8.8% for 2020 over the past 60 days.
Regeneron’s earnings estimates have been revised 6% upward for 2020 over the past 60 days. The stock has rallied 14.3% in the past year.
Trevena’s loss per share estimates have narrowed 26.4% for 2020 over the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
Axsome Therapeutics, Inc. (AXSM - Free Report) announced mixed top-line data from the phase III STRIDE-1 study evaluating its pipeline candidate AXS-05 to address patients with treatment resistant depression (TRD).
The primary endpoint following the week six of treatment did not reach any statistical significance in the above-mentioned study.
Nevertheless, the candidate met key secondary endpoints by demonstrating rapid and statistically significant improvements in depressive symptoms, per the Montgomery-Åsberg Depression Rating Scale (MADRS) measure at week one and for the overall six-week treatment period compared to the active comparator bupropion in the given patient population.
This randomized, double-blind, active-controlled study is assessing the safety and efficacy of AXS-05 for the aforementioned patient population. Based on results from the STRIDE-1 study, Axsome plans to initiate a second phase III study on AXS-05 in the third quarter of 2020 for addressing patients with TRD.
Shares of Axsome have skyrocketed 326.2% in the past year against the industry’s decline of 11.8%.
AXS-05 is a novel, oral, investigational non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity under development for treating central nervous system (CNS) disorder. Apart from the STRIDE-1 study, Axsome is conducting a phase III GEMINI study on AXS-05 for treating major depressive disorder (MDD) as well as a phase II/III ADVANCE-1 study on agitation associated with Alzheimer's disease (AD).
Per the company, positive outcomes from GEMINI study on MDD along with the previously-completed ASCEND study will be sufficient to support the filing of a new drug application (NDA) for AXS-05 to treat MDD. The NDA is expected to be filed in the fourth quarter of 2020.
In March 2020, Axsome announced that it is accelerating the completion time of the phase II/III ADVANCE-1 study on AXS-05. As a result, top-line findings from the study are now expected in early second-quarter 2020, which were previously awaited in the third. The study is currently enrolling patients aged 65 years and above.
Zacks Rank & Stocks to Consider
Axsome currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Acorda Therapeutics, Inc. , Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Trevena, Inc. (TRVN - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acorda’s loss per share estimates have narrowed 8.8% for 2020 over the past 60 days.
Regeneron’s earnings estimates have been revised 6% upward for 2020 over the past 60 days. The stock has rallied 14.3% in the past year.
Trevena’s loss per share estimates have narrowed 26.4% for 2020 over the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>